Amanda D. Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda D. Smith has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Zigmond
Pittsburgh Institute for Neurodegenerative Disease, University of Pittsburgh, 3501 Fifth Avenue, 7026 Biomedical Science Tower 3, Pittsburgh, PA, 15261, USA
2 shared publicationsAlexandra Emes
Pittsburgh Institute of Neurodegenerative Disease, University of Pittsburgh, Pittsburgh, PA 15213, USA
1 shared publication- Amina El Ayadi
Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA
1 shared publication Ann D. Cohen
Pittsburgh Institute for Neurodegenerative Diseases and Center for Neuroscience, University of Pittsburgh, PA, USA
1 shared publicationD.A. Kozlowski
1 shared publicationM.C. Bohn
Children's Memorial Research Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60614, USA
1 shared publication
Latest Publications
- Open Access
- 7 March 2022
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 12, 217-227
Blueberry juice augments exercise-induced neuroprotection in a Parkinson’s disease model through modulation of GDNF levels
- 7 March 2022
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 12, 217-227
Open AccessBlueberry juice augments exercise-induced neuroprotection in a Parkinson’s disease model through modulation of GDNF levels
- 19 February 2016
- Published by Springer Nature in Experimental Brain Research
- Vol. 234 (7) , 1863-1873
IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases
Insulin-like growth factor-1 (IGF-1) is an endogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including an acute animal model of Parkinson’s disease (PD). Motor deficits in PD are due largely to the progressive loss of nigrostriatal dopaminergic neurons. Thus, we examined the neuroprotective potential of IGF-1 in a progressive model of dopamine deficiency in which 6-hydroxydopamine (6-OHDA) is infused into the striatum. Rats received intrastriatal IGF-1 (5 or 50 µg) 6 h prior to infusion of 4 µg 6-OHDA into the same site and were euthanized 1 or 4 weeks later. Both concentrations of IGF-1 protected tyrosine hydroxylase (TH) immunoreactive terminals in striatum at 4 weeks but not at 1 week, indicating that IGF-induced restoration of the dopaminergic phenotype occurred over several weeks. TH-immunoreactive cell loss was only attenuated with 50 µg IGF-1. We then examined the effect of striatal IGF-1 on the Ras/ERK1/2 and PI3K/Akt pathways to ascertain whether their activation correlated with IGF-1-induced protection. Striatal and nigral levels of phospho-ERK1/2 were maximal 6 h after IGF-1 infusion and, with the exception of an increase in nigral pERK2 at 48 h, returned to basal levels by 7 days. Phospho-Akt (Ser473) was elevated 6-24 h post-IGF-1 infusion in both striatum and substantia nigra concomitant with inhibition of pro-death GSK-3β, a downstream target of Akt. These results suggest that IGF-1 can protect the nigrostriatal pathway in a progressive PD model and that this protection is preceded by activation of key pro-survival signaling cascades.
- 19 February 2016
- Published by Springer Nature in Experimental Brain Research
- Vol. 234 (7) , 1863-1873
IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases
Insulin-like growth factor-1 (IGF-1) is an endogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including an acute animal model of Parkinson’s disease (PD). Motor deficits in PD are due largely to the progressive loss of nigrostriatal dopaminergic neurons. Thus, we examined the neuroprotective potential of IGF-1 in a progressive model of dopamine deficiency in which 6-hydroxydopamine (6-OHDA) is infused into the striatum. Rats received intrastriatal IGF-1 (5 or 50 µg) 6 h prior to infusion of 4 µg 6-OHDA into the same site and were euthanized 1 or 4 weeks later. Both concentrations of IGF-1 protected tyrosine hydroxylase (TH) immunoreactive terminals in striatum at 4 weeks but not at 1 week, indicating that IGF-induced restoration of the dopaminergic phenotype occurred over several weeks. TH-immunoreactive cell loss was only attenuated with 50 µg IGF-1. We then examined the effect of striatal IGF-1 on the Ras/ERK1/2 and PI3K/Akt pathways to ascertain whether their activation correlated with IGF-1-induced protection. Striatal and nigral levels of phospho-ERK1/2 were maximal 6 h after IGF-1 infusion and, with the exception of an increase in nigral pERK2 at 48 h, returned to basal levels by 7 days. Phospho-Akt (Ser473) was elevated 6-24 h post-IGF-1 infusion in both striatum and substantia nigra concomitant with inhibition of pro-death GSK-3β, a downstream target of Akt. These results suggest that IGF-1 can protect the nigrostriatal pathway in a progressive PD model and that this protection is preceded by activation of key pro-survival signaling cascades.
- 1 January 2011
- Published by Elsevier in Brain Research
- Vol. 1370, 80-88
Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration
- 1 January 2011
- Published by Elsevier in Brain Research
- Vol. 1370, 80-88
Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration
- 1 June 2005
- Published by Elsevier in Experimental Neurology
- Vol. 193 (2) , 420-426
Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats
- 1 June 2005
- Published by Elsevier in Experimental Neurology
- Vol. 193 (2) , 420-426
Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats
- 1 October 2003
- Published by Elsevier in Molecular Brain Research
- Vol. 117 (2) , 129-138
Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRα1 and RET mRNAs in the adult rat
- 1 October 2003
- Published by Elsevier in Molecular Brain Research
- Vol. 117 (2) , 129-138
Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRα1 and RET mRNAs in the adult rat